Physician-scientist making medicines with friends, memories with family. EVP R&D at Amgen
Thousand Oaks, CA
Joined September 2011
- Tweets2.6K
- Following916
- Followers23.5K
- Likes5.2K
Jay Bradner, M.D. retweeted
#StandUpToCancer has joined forces with @MrBeast and @BeastPhilanthr to create a new SU2C Pediatric Cancer Dream Team focused on finding cures for kids with cancer, fueled by support from @Amgen and @StBaldricks. 🧡✨
1 in 5 children who are diagnosed with cancer will lose their lives to it. YOU can help change that. Donate today to help find cures at StandUpToCancer.org/MrBeastX.
Had the chance to spend time with Jimmy Donaldson (@MrBeast) talking about something that's often invisible: the research behind every breakthrough for children with cancer.
Thank you @SU2C for being such an incredible collaborator on this campaign.
Watch the video: amgen.ly/4x0WYhR
#mycompany
Very compelling mechanistic rationale for targeting the Fanconi and NHEJ pathways in Ewing Sarcoma. Figure 7 is impressive wrt Indusilam activity in models (RBM39 degradation). If therapeutic index exists or can be engendered, could be interesting. Enjoyed this study thoroughly.
New research from Alan D’Andrea, MD published in @MolecularCell reveals that Ewing Sarcoma has a profound DNA repair defect, making it a strong candidate for targeted therapy.
cell.com/molecular-cell/full…
All in the Simi Valley area and neighboring communities, please take note of this new Sandy Fire and wind patterns. Stay safe and take best care.
#BREAKING:
Fire crews are currently battling a brush fire in Simi Valley. @LAflyingcameras overhead NOW.
Tune in to KTLA 5 or stream via the KTLA app 📲, KTLA+ 💻 or KTLA.com
ICYMI. Singer and guitarist @ericchurch at UNC Commencement. Reflective, touching, deeply affecting. Will be watching this again with Jennifer and the kids.
Parked right next to it at the Waxahatchee & MJ Lenderman show last evening in LA. IYKYK, respect the total commitment. Incredible performance by @MarkJLenderman @k_crutchfield @waxa_katie
Very nice study by @wgibson, on bifunctionals in gene control. The EWS-FLI1 signature impact of the JQ1-based recruiter is nice. Worth studying the AR-binding JQ1 ligands from Halda/JNJ, in this way. Contribution of RIPTAC and TCIP components would be very interesting. (Also curious if the potent aTAG-2 acetylates EWS-FLI1 or the chimeric FKBP12). Great read, Will!
Jay Bradner, M.D. retweeted
What if a small molecule could activate a transcription factor program in one cell type and destroy the same pathway in another? In our new preprint, we describe one such story on bifunctional molecules that toggle between transactivation and repression.
Telomeres are longer on the West Coast. Been in SoCal for only eight months and can already feel it. Nice GWAS on leukocyte telomere length and genetic associations in @NatureGenet by @pnatarajanmd and colleagues. nature.com/articles/s41588-0…
Learned today of the passing of Phil Low, a drug hunter, scholar, educator and just lovely man. His work to target cancer cells via folic acid receptors, among so many other creative ideas, were a source of inspiration so many years ago. It was an honor to work with him on PSMA radioligand therapy, and to develop his inventions further to real medicines while at Novartis. Phil was a dynamo in his Purdue laboratory, surrounded by adoring trainees, at a whiteboard or pounding through 80 packed Powerpoint slides in 30 breathless minutes. I am glad and better to have known you, Phil. Your memory is a blessing. linkedin.com/posts/purdue-un…
Mitochondria and Chloroplasts set aside their differences (cellular respiration vs photosynthesis, oxygen vs light, christae vs thylakoids) @GordonConf this July. @VamsiMootha accepting abstracts and terminal electrons now.
If you love the organelles that power life, come to @GordonConf Mito & Chloroplasts July 19-24, Maine. Please RT.
This conference (rich tradition!) will span the evolution, metabolism, and synthetic biology of these organelles.
Many oral/poster slots:
tinyurl.com/5n6upfxr
Had the pleasure of joining fellow biotech leaders at the #LongwoodHealthcareLeaders #SanFranciscoCEO meeting for a candid discussion on where R&D is headed — and how our industry must continue to evolve to meet unmet patient needs and deliver meaningful innovation.
Thank you to @LongwoodLeaders and @LongwoodFund for convening such a thoughtful group and for the opportunity to share how @Amgen is designing the medicines of tomorrow.
Thanks Bruce @LifeSciVC. Time cannot move fast enough to bring this brave idea and prototype medicine to patients with AML. As a stem cell transplant physician, I am well calibrated to the challenge AML patients face. All learnings, insights and leaders at @Amgen in ALL will be accessible to this amazing team of innovators.
Great to see early stage deal-making in important high need areas like AML, securing preclinical assets on novel/emerging targets. Kudos to $AMGN and @jaybradner...
For Dark Blue, having raised only ~$10M of investor capital, at at post-money of ~$20M (according to Pitchbook), this is likely a handsome return upfront and puts the asset in the hands of a smart developer.
Having M&A alternatives for preclinical assets helps drive competitive investor demand across the board, creating healthy optionality (vs a dilution-heavy, IPO-only strategy).
Stunning use of dTAG to study rapid dynamics of chromatin structure and cis-regulatory interactions at high resolution. Blueprint for studying mechanistic effects of TF degraders / modulators.
In the latest issue! Mapping chromatin structure at base-pair resolution unveils a unified model of cis-regulatory element interactions dlvr.it/TPpqpW
An inspired choice to lead a brilliant faculty of scholars. Congratulations, @mskcc CSO Ross Levine. I knew him when, and knew it then.
Dr. Ross Levine (@rosslevinemd), Senior Vice President of Translational Research at MSK, has been named MSK's new Chief Scientific Officer (CSO).
Dr. Levine will be responsible for setting and leading strategy for basic and translational research, including programs, centers, and technology cores.
Congratulations, Dr. Levine!
bit.ly/4nQAeNj
How to Succeed in Biotech. Part 2 of this thoughtful and insight-rich reflection by Bruce Booth @LifeSciVC, on the eve of his 20th Altas-versary. Plain spoken and approachable, a high yielding reaction. Great read whether working at a small biotech or the largest independent biotech in the world.
Twenty Years In Early Stage Biotech VC (Part 2): People
Continuing in the trifecta of anniversary blogs, here are a few observations on people, talent and teams:
· The power of luck!
· Life is short… live by the NAR (No Asshole Rule)
· By the time you know you need a leadership change, you’re probably late
· Surround yourself with data-driven truth-seekers
· The best CEOs understand and are aligned with their current shareholders
· Most CEOs are either openers or closers, rarely both
· Build lean organizations by encouraging teams to “earn the right” to grow
· Fractional leadership in a startup works until it doesn’t.
· Leadership coaches/advisors are valuable for all types of performers
· Build authentic multi-faceted relationships with people in your biotech community
lifescivc.com/2025/10/twenty…